Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import

Journal of Cell Science

Volumn 128, Issue 22, 2015, Pages 4151-4159

  Darovic, Simona ^a   Mihevc, Sonja Prpar ^a   Župunski, Vera ^b   Gunčar, Gregor ^b   Štalekar, Maja ^a   Lee, Youn Bok ^c   Shaw, Christopher E ^c   Rogelj, Boris ^a,d  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Biomedical Research Institute BRIS   (Slovenia)

Author keywords

Amyotrophic lateral sclerosis; Frontotemporal lobar degeneration; FUS; Nuclear import; Phosphorylation; Transportin 1

Indexed keywords

TYROSINE; FUS PROTEIN, HUMAN; KARYOPHERIN BETA; RNA BINDING PROTEIN FUS; TNPO1 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR IMPORT; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RAT; ACTIVE TRANSPORT; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL DEMENTIA; GENETICS; HELA CELL LINE; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BETA KARYOPHERINS; FRONTOTEMPORAL LOBAR DEGENERATION; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RNA-BINDING PROTEIN FUS; TYROSINE;

EID: 84949844936     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.176602     Document Type: Article

References (54)

1. Aoki, N., Higashi, S., Kawakami, I., Kobayashi, Z., Hosokawa, M., Katsuse, O., Togo, T., Hirayasu, Y. and Akiyama, H. (2012). Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathol. 124, 383-394.
2. Baumer, D., Hilton, D., Paine, S. M. L., Turner, M. R., Lowe, J., Talbot, K. and Ansorge, O. (2010). Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 75, 611-618.
3. Belly, A., Moreau-Gachelin, F., Sadoul, R. and Goldberg, Y. (2005). Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: exclusion from the nucleus and accumulation in dendritic granules and spine heads. Neurosci. Lett. 379, 152-157.
4. Blair, I. P., Williams, K. L., Warraich, S. T., Durnall, J. C., Thoeng, A. D., Manavis, J., Blumbergs, P. C., Vucic, S., Kiernan, M. C. and Nicholson, G. A. (2010). FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J. Neurol. Neurosurg. Psychiatry 81, 639-645.
5. Blom, N., Sicheritz-Pontén, T., Gupta, R., Gammeltoft, S. and Brunak, S. (2004). Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633-1649.
6. Boillee, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G. and Cleveland, D.W. (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392.
7. Bosco, D. A., Lemay, N., Ko, H. K., Zhou, H., Burke, C., Kwiatkowski, T. J., Jr, Sapp, P., McKenna-Yasek, D., Brown, R. H., Jr and Hayward, L. J. (2010). Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 19, 4160-4175.
8. Brelstaff, J., Lashley, T., Holton, J. L., Lees, A. J., Rossor, M. N., Bandopadhyay, R. and Revesz, T. (2011). Transportin1: a marker of FTLDFUS. Acta Neuropathol. 122, 591-600.
9. Conte, A., Lattante, S., Zollino, M., Marangi, G., Luigetti, M., Del Grande, A., Servidei, S., Trombetta, F. and Sabatelli, M. (2012). P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul. Disord. 22, 73-75.
10. Derkinderen, P., Scales, T. M. E., Hanger, D. P., Leung, K.-Y., Byers, H. L., Ward, M. A., Lenz, C., Price, C., Bird, I. N., Perera, T. et al. (2005). Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci. 25, 6584-6593.
11. Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M. E., Mackenzie, I. R. A., Capell, A., Schmid, B. et al. (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841-2857.
12. Dormann, D., Madl, T., Valori, C. F., Bentmann, E., Tahirovic, S., Abou-Ajram, C., Kremmer, E., Ansorge, O., Mackenzie, I. R. A., Neumann, M. et al. (2012). Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 31, 4258-4275.
13. Emsley, P., Lohkamp, B., Scott, W. G. and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501.
14. Gal, J., Zhang, J., Kwinter, D. M., Zhai, J., Jia, H., Jia, J. and Zhu, H. (2011). Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol. Aging 32, 2323.e2327-e2340.
15. Gordon, J. A. (1991). Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201, 477-482.
16. Guttinger, S., Muhlhausser, P., Koller-Eichhorn, R., Brennecke, J. and Kutay, U. (2004). Transportin2 functions as importin and mediates nuclear import of HuR. Proc. Natl. Acad. Sci. USA 101, 2918-2923.
17. Huang, E. J., Zhang, J., Geser, F., Trojanowski, J. Q., Strober, J. B., Dickson, D.W., Brown, R. H., Jr, Shapiro, B. E. and Lomen-Hoerth, C. (2010). Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol. 20, 1069-1076.
18. Hung, C.-J., Lee, Y.-J., Chen, D.-H. and Li, C. (2009). Proteomic analysis of methylarginine-containing proteins in HeLa cells by two-dimensional gel electrophoresis and immunoblotting with a methylarginine-specific antibody. Protein J. 28, 139-147.
19. Huyer, G., Liu, S., Kelly, J., Moffat, J., Payette, P., Kennedy, B., Tsaprailis, G., Gresser, M. J. and Ramachandran, C. (1997). Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843-851.
20. Kwiatkowski, T. J., Jr, Bosco, D. A., LeClerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T. et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
21. Lashley, T., Rohrer, J. D., Bandopadhyay, R., Fry, C., Ahmed, Z., Isaacs, A. M., Brelstaff, J. H., Borroni, B., Warren, J. D., Troakes, C. et al. (2011). A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134, 2548-2564.
22. Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Do, L. H., Andreadis, A., Van Hoesen, G. and Ksiezak-Reding, H. (2004). Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci. 24, 2304-2312.
23. Lee, B. J., Cansizoglu, A. E., Süel, K. E., Louis, T. H., Zhang, Z. and Chook, Y. M. (2006). Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell 126, 543-558.
24. Leemann-Zakaryan, R. P., Pahlich, S., Grossenbacher, D. and Gehring, H. (2011). Tyrosine Phosphorylation in the C-Terminal nuclear localization and retention signal (C-NLS) of the EWS protein. Sarcoma 2011, 218483.
25. Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K. et al. (1999). Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661.
26. Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E. et al. (2010). Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1-4.
27. Mackenzie, I. R. A., Ansorge, O., Strong, M., Bilbao, J., Zinman, L., Ang, L.-C., Baker, M., Stewart, H., Eisen, A., Rademakers, R. et al. (2011). Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. Acta Neuropathol. 122, 87-98.
28. Marko, M., Vlassis, A., Guialis, A. and Leichter, M. (2012). Domains involved in TAF15 subcellular localisation: dependence on cell type and ongoing transcription. Gene 506, 331-338.
29. Mitchell, J. D. and Borasio, G. D. (2007). Amyotrophic lateral sclerosis. Lancet 369, 2031-2041.
30. Munoz, D. G., Neumann, M., Kusaka, H., Yokota, O., Ishihara, K., Terada, S., Kuroda, S. and Mackenzie, I. R. (2009). FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617-627.
31. Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H. A. and Mackenzie, I. R. A. (2009a). A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922-2931.
32. Neumann, M., Roeber, S., Kretzschmar, H. A., Rademakers, R., Baker, M. and Mackenzie, I. R. A. (2009b). Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol. 118, 605-616.
33. Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., Ansorge, O., Roeber, S., Kretzschmar, H. A., Munoz, D. G., Kusaka, H. et al. (2011). FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595-2609.
34. Neumann, M., Valori, C. F., Ansorge, O., Kretzschmar, H. A., Munoz, D. G., Kusaka, H., Yokota, O., Ishihara, K., Ang, L.-C., Bilbao, J. M. et al. (2012). Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 124, 705-716.
35. Nishimura, A. L., Zupunski, V., Troakes, C., Kathe, C., Fratta, P., Howell, M., Gallo, J.-M., Hortobagyi, T., Shaw, C. E. and Rogelj, B. (2010). Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763-1771.
36. Niu, C., Zhang, J., Gao, F., Yang, L., Jia, M., Zhu, H. and Gong, W. (2012). FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS ONE 7, e47056.
37. Rademakers, R., Stewart, H., Dejesus-Hernandez, M., Krieger, C., Graff-Radford, N., Fabros, M., Briemberg, H., Cashman, N., Eisen, A. and Mackenzie, I. R. A. (2010). Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve 42, 170-176.
38. Rappsilber, J., Friesen, W. J., Paushkin, S., Dreyfuss, G. and Mann, M. (2003). Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal Chem. 75, 3107-3114.
39. Scales, T. M. E., Derkinderen, P., Leung, K.-Y., Byers, H. L., Ward, M. A., Price, C., Bird, I. N., Perera, T., Kellie, S., Williamson, R. et al. (2011). Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn. Mol. Neurodegener. 6, 12.
40. Scaramuzzino, C., Monaghan, J., Milioto, C., Lanson, N. A., Jr, Maltare, A., Aggarwal, T., Casci, I., Fackelmayer, F. O., Pennuto, M. and Pandey, U. B. (2013). Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLoS ONE 8, e61576.
41. Seelaar, H., Klijnsma, K. Y., de Koning, I., van der Lugt, A., Chiu, W. Z., Azmani, A., Rozemuller, A. J. M. and van Swieten, J. C. (2010). Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J. Neurol. 257, 747-753.
42. Snowden, J. S., Hu, Q., Rollinson, S., Halliwell, N., Robinson, A., Davidson, Y. S., Momeni, P., Baborie, A., Griffiths, T. D., Jaros, E. et al. (2011). The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol. 122, 99-110.
43. Terry, L. J., Shows, E. B. and Wente, S. R. (2007). Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 318, 1412-1416.
44. Tradewell, M. L., Yu, Z., Tibshirani, M., Boulanger, M.-C., Durham, H. D. and Richard, S. (2012). Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 21, 136-149.
45. Troakes, C., Hortobágyi, T., Vance, C., Al-Sarraj, S., Rogelj, B. and Shaw, C. E. (2013). Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it fromfrontotemporal lobar degeneration with FUS inclusions. Neuropathol. Appl. Neurobiol. 39, 553-561.
46. Uezu, A., Okada, H., Murakoshi, H., del Vescovo, C. D., Yasuda, R., Diviani, D. and Soderling, S. H. (2012). Modified SH2 domain to phototrap and identify phosphotyrosine proteins from subcellular sites within cells. Proc. Natl. Acad. Sci. USA 109, E2929-E2938.
47. Urwin, H., Josephs, K. A., Rohrer, J. D., Mackenzie, I. R., Neumann, M., Authier, A., Seelaar, H., Van Swieten, J. C., Brown, J. M., Johannsen, P. et al. (2010). FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33-41.
48. Usardi, A., Pooler, A. M., Seereeram, A., Reynolds, C. H., Derkinderen, P., Anderton, B., Hanger, D. P., Noble, W. and Williamson, R. (2011). Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J. 278, 2927-2937.
49. Van Langenhove, T., van der Zee, J. and Van Broeckhoven, C. (2012). The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann. Med. 44, 817-828.
50. Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
51. Vance, C., Scotter, E. L., Nishimura, A. L., Troakes, C., Mitchell, J. C., Kathe, C., Urwin, H., Manser, C., Miller, C. C., Hortobagyi, T. et al. (2013). ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 22, 2676-2688.
52. Yamaguchi, A. and Kitajo, K. (2012). The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS. PLoS ONE 7, e49267.
53. Zakaryan, R. P. and Gehring, H. (2006). Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. J. Mol. Biol. 363, 27-38.
54. Zhang, Z. C. and Chook, Y. M. (2012). Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). Proc. Natl. Acad. Sci. USA 109, 12017-12021.